Lenvatinib
Lenvima · VEGFR TKI
Highest-ranked TKI for hypertension; proteinuria.
Cabometyx · Cabo
VEGFR/MET TKI · approved 2012 · 10 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A VEGFR/MET TKI whose antiangiogenic reach brings hypertension, proteinuria and occasional nephrotic-range injury.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Hypertension and proteinuria are common; in pivotal RCC trials (e.g., METEOR, CABOSUN) hypertension was among the most frequent adverse events with grade >=3 rates around 15-28%. Cabozantinib is one of the TKIs most often associated with proteinuria, with case reports of nephrotic syndrome. Reported rate: grade >=3 hypertension in 15% — Adults with advanced/metastatic clear-cell renal cell carcinoma previously treated with >=1 VEGFR tyrosine-kinase… (Choueiri 2016, PMID 27279544).Source: Nervo et al., Crit Rev Oncol Hematol 2021; METEOR (Choueiri, NEJM 2015)
Within weeks of starting therapy.
Distilled from: “Within weeks of starting therapy.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Most common anti-angiogenic adverse event; significantly increased risk vs control (all-grade RR 5.48, 95% CI 3.76-7.99; high-grade RR 5.09) in a meta-analysis of 8 trials (n=1,514), with higher high-grade risk than sorafenib, sunitinib, vandetanib or pazopanib. PMID 27181268 (opens PubMed in a new tab)
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Tap a signature to trace where it strikes the nephron.
Representative grade ≥3 incidence
Hypertension strikes: Glomerulus, Vasculature / Endothelium.
Hypertension
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
§ Receptor target map
VEGFR2 is the target with documented renal consequences across every VEGFR TKI; multi-kinase breadth beyond it (PDGFR-β, FGFR, and off-target receptor kinases) adds further renal and hypertensive liability. Select a lit receptor for its renal consequence.
VEGFR2 · renal target
Glomerular endothelial VEGFR2: loss of podocyte-derived paracrine VEGF signaling → fenestrae loss, nephrin downregulation, nitric-oxide depletion → hypertension, proteinuria, and thrombotic microangiopathy. Cabozantinib carries among the highest antiangiogenic hypertension burden of the class (all-grade RR ~5.5).
Oral multikinase inhibitor of VEGFR2, MET, AXL, RET, KIT and others, simultaneously blocking angiogenesis and MET/AXL-driven tumor-cell signaling and invasion (the MET/AXL activity is thought to counter VEGFR-inhibitor escape). Used in renal cell carcinoma, hepatocellular carcinoma and medullary/differentiated thyroid cancer.
Class-level context for the major non-renal toxicities of the VEGFR/MET TKI class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: RISK OF SERIOUS ADVERSE REACTIONS OR REDUCED EFFECTIVENESS DUE TO MEDICATION ERRORS OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products. Inappropriate substitution or incorrect conversion of OMCAZIO capsules for another cabozantinib product can increase the risk of serious adverse reactions. Confirm that the intended cabozantinib product at the intended dosage and strength is being prescribed and dispensed. ( 2.1 , 2.3 , 5.1 ) WARNING: RISK OF SERIOUS ADVERSE REACTIONS OR REDUCED EFFECTIVENESS DUE TO MEDICATION ERRORS See full prescribing information for complete boxed warning . OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products. Inappropriate substitution or incorrect conversion of OMCAZIO capsules for another cabozantinib product can increase the risk of serious adverse reactions. Confirm that the intended cabozantinib product at the intended dosage and strength is being prescribed and dispensed. ( 2.1 , 2.3 , 5.1 )
Kidney rows of the label's dosage tables
From the CABOMETYX label (Oct 2025) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. A cell marked fn carries one of those footnotes on the label. Educational only, not medical advice.
| Adverse Reaction | Severityfn | CABOMETYX Dosage Modification |
|---|---|---|
| Proteinuria [see Warnings and Precautions (5.10)] | Grade 2 or 3 | Withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria Resume at a reduced dose Permanently discontinue CABOMETYX for nephrotic syndrome |
Everything below is FAERS — adverse events someone chose to report, about 48,250 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
5,439 of 48,250 reports
Reported with hospitalization
9,281 of 48,250 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 522 of the 48,250 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Cabozantinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Lenvima · VEGFR TKI
Highest-ranked TKI for hypertension; proteinuria.
Stivarga · VEGFR TKI
Hypertension and proteinuria.
Fotivda · VEGFR TKI
Hypertension and proteinuria in RCC.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Cabozantinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Cabozantinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 28 clinical records among all 33 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.